KYKangrui Yuan

Kangrui Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kangrui Yuan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dauricine Mitigates Hypoxia Through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation

    by Zengxun Ni, Zineng Zhou, Feipeng Jia, Jingcheng Wu, Junhao Qiu, Kangrui Yuan, Zhicheng Jia

    Hypoxia is a prevalent pathophysiological condition. Prolonged exposure to hypobaric hypoxia can lead to maladaptation, increasing the risk of chronic hypoxic diseases such as high-altitude polycythemia (HAPC). Dauricine, an alkaloid derived from the root of Menispermum dauricum DC, has been demonstrated to possess anti-hypoxic properties; however, its underlying molecular mechanisms remain elusive. In this study, a potential multi-target anti-hypoxic mechanism of dauricine was proposed and computationally evaluated using an integrated approach combining network pharmacology, molecular docking, and molecular dynamics simulations. Common targets between dauricine and hypoxia-related genes were identified through network pharmacology screening. A protein–protein interaction (PPI) network was constructed to identify core targets, followed by Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Molecular docking was subsequently employed to evaluate the binding affinities between dauricine and the candidate core targets, while molecular dynamics simulations were performed to assess the dynamic stability of the resulting complexes. Additionally, the drug-likeness and safety profiles of dauricine were assessed. The results suggest that dauricine may exert its anti-hypoxic effects by modulating candidate core targets, including ESR1, PIK3CA, and MTOR, and by acting on key signaling pathways such as PI3K-Akt, MAPK, and mTOR. This study provides a theoretical foundation for the further investigation of dauricine as a multi-target candidate for intervention in hypoxia and establishes a bioinformatics basis for subsequent experimental validation.

  • Open Access

    Dauricine Mitigates Hypoxia through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation

    by Zengxun Ni, Zineng Zhou, Feipeng Jia, Jingcheng Wu, Junhao Qiu, Kangrui Yuan, Zhicheng Jia

    Hypoxia is a prevalent pathophysiological condition. Prolonged exposure to hypobaric hypoxia can lead to maladaptation, increasing the risk of chronic hypoxic diseases such as high-altitude polycythemia (HAPC). Dauricine, an alkaloid derived from the root of Menispermum dauricum DC, has been demonstrated to possess anti-hypoxic properties; however, its underlying molecular mechanisms remain elusive. In this study, a multi-target molecular mechanism of dauricine in mitigating hypoxia was systematically investigated using an integrated approach combining network pharmacology, molecular docking, and molecular dynamics simulations. Common targets between dauricine and hypoxia-related genes were identified through network pharmacology screening. A protein-protein interaction (PPI) network was constructed to identify core targets, followed by Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Molecular docking was subsequently employed to evaluate the binding affinities between dauricine and the core targets, while molecular dynamics simulations were performed to validate the stability of the resulting complexes. Additionally, the drug-likeness and safety profiles of dauricine were assessed. The results indicate that dauricine may exert its anti-hypoxic effects by modulating core targets, including ESR1, PIK3CA, and MTOR, and by acting on key signaling pathways such as PI3K-Akt, MAPK, and mTOR. This study provides a theoretical foundation for the development of dauricine as a multi-target candidate for intervention in hypoxia and establishes a bioinformatics basis for subsequent experimental validation.

  • Open Access

    A pH-responsive mesoporous Zn-MOF nanocarrier for efficient cisplatin delivery and inhibition of A549 cancer cells

    by Xiaomei Ye, Shuzhen Lu, Hao Peng, Zhirong Huang, Chunyu Pan, Yayan Huang, Kangrui Yuan, Youfa Qin

    Mesoporous metal-organic frameworks (MOFs) have the advantages of high specific surface area, tunable pore size, and favorable biocompatibility, making them promising candidates for drug delivery in cancer therapy. In this study, a series of mesoporous zinc-based MOF, constructed using cyclopentane dicarboxylic acid as the organic linker, was successfully synthesized via a surfactant-assisted solvothermal method. Surface characterization revealed that MOF-2 exhibited high surface area (1325 m2/g), pore volume (0.273 cm3/g), and average pore diameter (5.69 nm). UV-Vis analysis showed that MOF-2 demonstrated improved drug loading (18% w/w), encapsulation efficiency (86%), and cumulative release (96%), along with both pH-responsive degradation and drug release properties. Furthermore, cisplatin-loaded MOF-2 exhibited potent antitumor activity against A549 cells and effectively inhibited cell migration and invasion, while maintaining minimal cytotoxicity toward LO2 normal hepatic cells. These findings suggest MOF-2 as a promising nanocarrier for pH-responsive anticancer drug delivery. Graphical Abstract